Tiziana Life Sciences' Chairman purchased shares, indicating confidence in intranasal foralumab's potential for treating multiple sclerosis.
Quiver AI Summary
Tiziana Life Sciences, a biotechnology company focused on developing innovative immunomodulation therapies, has announced that its Executive Chairman, Gabriele Cerrone, has acquired an additional 25,000 common shares at $1.60 each, increasing his ownership to 36.28% of the company's total shares. The lead compound, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in stimulating T regulatory cells and is currently being tested in a Phase 2a clinical trial for patients with non-active secondary progressive multiple sclerosis. This drug candidate is notable for its novel intranasal delivery method, which aims to enhance efficacy and safety compared to traditional intravenous administration. Tiziana further highlights its commitment to advancing immunotherapy through this unique delivery technology, with multiple applications pending.
Potential Positives
- Executive Chairman and Founder Gabriele Cerrone's purchase of 25,000 shares signals strong personal investment and confidence in the company's future, increasing his total ownership to 36.28% of the company.
- The ongoing clinical trials for intranasal foralumab show promising early results, with all dosed patients demonstrating either improvement or disease stability, indicating potential efficacy of the treatment.
- Tiziana is pioneering the use of intranasal delivery for immunomodulation therapies, which may enhance efficacy and safety compared to traditional intravenous methods, showcasing innovation in drug delivery technology.
- As the only fully human anti-CD3 monoclonal antibody in clinical development, intranasal foralumab positions Tiziana uniquely in the market, potentially leading to significant competitive advantages.
Potential Negatives
- The press release lacks detailed information on the results of the ongoing clinical trials for intranasal foralumab, potentially raising concerns about transparency regarding its effectiveness and safety.
- The mention of “non-active” secondary progressive multiple sclerosis may indicate a limited patient population, which could affect the perceived scope and market potential of the treatment.
- The concentration of share ownership by the Executive Chairman, holding 36.28% of issued share capital, might raise concerns about governance and potential conflicts of interest.
FAQ
Who is Gabriele Cerrone in Tiziana Life Sciences?
Gabriele Cerrone is the Executive Chairman and Founder of Tiziana Life Sciences, actively involved in the company's operations.
What is intranasal foralumab?
Intranasal foralumab is a fully human anti-CD3 monoclonal antibody being developed for immunomodulation therapies, particularly for neurodegenerative diseases.
What diseases is foralumab being studied for?
Foralumab is currently being studied for non-active secondary progressive multiple sclerosis (na-SPMS) in clinical trials.
What significant progress has Tiziana made with foralumab?
Tiziana has dosed 10 patients in an open-label program showing positive responses, and a Phase 2 trial is underway.
How does Tiziana's delivery method differ from traditional methods?
Tiziana's innovative nasal approach aims to enhance the efficacy, safety, and tolerability of immunotherapy compared to intravenous delivery.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TLSA Hedge Fund Activity
We have seen 12 institutional investors add shares of $TLSA stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC added 1,679,043 shares (+96.5%) to their portfolio in Q2 2025, for an estimated $2,652,887
- CITADEL ADVISORS LLC added 198,990 shares (+inf%) to their portfolio in Q2 2025, for an estimated $314,404
- OMERS ADMINISTRATION CORP removed 144,900 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $228,942
- JANE STREET GROUP, LLC removed 142,578 shares (-85.1%) from their portfolio in Q2 2025, for an estimated $225,273
- SIMPLEX TRADING, LLC added 67,251 shares (+inf%) to their portfolio in Q2 2025, for an estimated $106,256
- MORGAN STANLEY removed 65,761 shares (-47.3%) from their portfolio in Q2 2025, for an estimated $103,902
- BARCLAYS PLC removed 47,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $51,300
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program ( NCT06802328 ) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis ( NCT06292923 ).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. [1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com .
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email:
[email protected]
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
